AH 23848 (calcium salt)

AH 23848 (calcium salt)

CAT N°: 19023
Price:

From 122.00 103.70

Thromboxane (TXA2) activates the T prostanoid (TP) receptor. Prostaglandin E2 (PGE2) activates four E prostanoid (EP) receptors, EP1-4. AH 23848 is a dual antagonist of TP and EP4 receptors.{3339,1755} It originally was found to inhibit TXA2-induced platelet aggregation (IC50 = 0.26 ?M) and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619.{3339,1756} AH 23848 was subsequently demonstrated to impair PGE2-mediated relaxation of piglet saphenous vein by antagonizing the PGE2 receptor EP4.{1755} By inhibiting EP4, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, and the proliferation of fibroblasts, as well as reduces metastasis in a mouse model of metastatic breast cancer.{16771,14694}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (4Z)-rel-7-[(1R,2R,5S)-5-([1,1′-biphenyl]-4-ylmethoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid, hemicalcium salt
  • Correlated keywords
    • 81739-45-9 81443-73-4 AH23848 TXA-2 PGE-2 EP1 EP2 EP3 EP4 U46619
  • Product Overview:
    Thromboxane (TXA2) activates the T prostanoid (TP) receptor. Prostaglandin E2 (PGE2) activates four E prostanoid (EP) receptors, EP1-4. AH 23848 is a dual antagonist of TP and EP4 receptors.{3339,1755} It originally was found to inhibit TXA2-induced platelet aggregation (IC50 = 0.26 ?M) and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619.{3339,1756} AH 23848 was subsequently demonstrated to impair PGE2-mediated relaxation of piglet saphenous vein by antagonizing the PGE2 receptor EP4.{1755} By inhibiting EP4, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, and the proliferation of fibroblasts, as well as reduces metastasis in a mouse model of metastatic breast cancer.{16771,14694}

We also advise you